LND Extent During Prostate Cancer Surgery Not Linked to Survival
A study of men with prostate cancer found no association between extent of lymph node dissection during radical prostatectomy and survival outcomes.
American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium
Oral HIF-2α Inhibitor Belzutifan Upholds Clinical Activity in RCC
Todd Bauer, MD, presents updated data from a phase 1/2 study of the oral hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan.
Sexual Orientation May Influence Choice to Pursue Screening for ‘Gender-Specific’ Cancers
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Race Reporting in GU Cancers Indicates Relative Overrepresentation of White Individuals
Lythgoe et al studied patterns of race reporting in genitourinary (GU)
cancer trials.
Radium-223/Enzalutamide Combination Therapy Could Improve Outcomes in Progressive mCRPC
Kessel et al present the final efficacy and safety results from a phase 2 study of radium-223 plus enzalutamide vs enzalutamide monotherapy in metastatic castration-resistant prostate cancer (mCRPC).
Final Analysis of ARAMIS Trial Confirms Significant OS Benefit With Darolutamide in nmCRPC
Sensitivity analyses were performed to assess the effect of placebo to darolutamide crossover on overall survival benefit among ARAMIS trial participants.
Active Surveillance Appropriate for Favorable Intermediate-Risk PCa
Active surveillance may help many men with favorable intermediate-risk prostate cancer to avoid the adverse effects of treatment for 5 years.
NLR Rise May Predict Mortality, Treatment Failure Risks in mRCC
A rise in neutrophil-to-lymphocyte ratio of 3 or more after 2 months of therapy is associated with an increased risk for death in less than 1 year and treatment failure in less than 6 months, according to investigators.
Olaparib Has Limited Antitumor Activity Against Some HRR Genes in mCRPC
Olaparib had greater antitumor activity against BRCA1/2-mutant metastatic castration-resistant prostate cancer (mCRPC).
No Association Between ADT and SARS-CoV-2 Infection in Prostate Cancer
The aim of this study was to determine whether androgen deprivation therapy (ADT) affords protection against SARS-CoV-2 infection in a population of patients with prostate cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...